目的 探討降糖舒膠囊聯(lián)合利格列汀治療2型糖尿病的臨床效果。方法 選取2017年1月—2019年1月鎮(zhèn)平縣人民醫(yī)院收治的2型糖尿病患者106例，隨機分成對照組（53例）和治療組（53例）。對照組患者晨服利格列汀片，5 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服降糖舒膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療12周。觀察兩組患者臨床療效，同時比較治療前后兩組患者糖脂代謝指標空腹血糖（FPG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbA1c）、三酰甘油（TG）和高密度脂蛋白膽固醇（HDL-C），胰島功能指標李光偉指數(shù)（IAI）和胰島β細胞功能指數(shù)（HOMA-β），血流變學指標全血高切黏度（HBV）、全血低切黏度（LBV）、血漿黏度（PV）、紅細胞變形指數(shù)（EDI）及氧化應(yīng)激指標超氧化物歧化酶（SOD）、丙二醛（MDA）和SOD/MDA。結(jié)果 治療后，對照組臨床有效率83.02%，顯著低于治療組的96.23%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者血清FPG、2 h PG、HbA1c和TG水平均顯著降低（P<0.05），但血清HDL-C濃度均顯著升高（P<0.05）；且治療后治療組糖脂代謝參數(shù)明顯好于對照組（P<0.05）。治療后，兩組患者IAI、HOMA-β值顯著升高（P<0.05），且治療組IAI和HOMA-β值均顯著高于對照組（P<0.05）。治療后，兩組患者血流變學指標HBV、LBV、PV、EDI值顯著降低（P<0.05），且治療組比對照組下降更顯著（P<0.05）。治療后，兩組患者血清SOD水平和SOD/MDA比值顯著上升（P<0.05），而MDA水平顯著減少（P<0.05）；且治療組上述氧化應(yīng)激參數(shù)比對照組改善更顯著（P<0.05）。結(jié)論 降糖舒膠囊聯(lián)合利格列汀治療2型糖尿病有助于維持患者血糖穩(wěn)定，正性調(diào)節(jié)體內(nèi)脂代謝紊亂，增強胰島素敏感性，保護胰島β細胞功能，抑制機體氧化應(yīng)激。

Objective To investigate the clinical effect of Jiangtangshu Capsules combined with linagliptin in treatment of type 2 diabetes mellitus. Methods Patients (106 cases) with type 2 diabetes mellitus in Zhenping County People's Hospital from January 2017 to January 2019 were randomly divided into control (53 cases) and treatment (53 cases) groups. Patients in the control group were po administered with Linagliptin Tablets in the morning, 5 mg/time, once daily. Patients in the treatment group were po administered with Jiangtangshu Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the glucose and lipid metabolism indices of FPG, 2 h PG, HbA1c, TG and HDL-C, islet function indexes of IAI and HOMA-β, hemorheological indexes of HBV, LBV, PV, EDI, and the oxidative stress index levels of SOD、SOD/MDA and MDA in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 83.02%, which was significantly lower than 96.23% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the glucose and lipid metabolism indices of FPG, 2 h PG, HbA1c, TG in two groups were significantly decreased (P<0.05), but the HDL-C levels were significantly increased (P<0.05), and these indices in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the islet function indexes of IAI and HOMA-β in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the hemorheological indexes of HBV, LBV, PV, and EDI in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the oxidative stress index levels of SOD and SOD/MDA in two groups were significantly increased (P<0.05), but the MDA levels were significantly decreased (P<0.05), and these indexes levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Jiangtangshu Capsules combined with linagliptin in treatment of type 2 diabetes mellitus is helpful to maintain blood glucose stability, positively regulate lipid metabolism disorders, enhance insulin sensitivity, protect islet β cell function, improve blood rheology, and inhibit oxidative stress.

R977

河南省衛(wèi)計委科研課題（201605A3086）